Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Comparison of Topical Nanocolloidal Silver Formulation Use With Eosin 2% Solution in Management of Hard-To-Heal Ulcers in Patients With Pemphigus Vulgaris Publisher Pubmed



Abedini R1 ; Mahmoudi H1 ; Kordestani S2, 3 ; Habib FN2 ; Abyaneh M3 ; Rahemi H3
Authors
Show Affiliations
Authors Affiliations
  1. 1. Tehran University of Medical Sciences, Dermatology Department, Razi Hospital, Iran
  2. 2. Medical Engineering Department, Amirkabir University of Technology, Tehran, Iran
  3. 3. ChitoTech Inc, Unit 9and11, East Wing, Somayeh Avenue, Tehran, Iran

Source: Journal of Wound Care Published:2020


Abstract

[No abstract available]
Related Docs
View other Related Docs
1. Rituximab in Practice: Clinical Evaluation of Patients With Pemphigus After Rituximab Administration, Dermatologic Therapy (2021)
2. Intralesional Injection of Biosimilar Rituximab in Recalcitrant Mucocutaneous Lesions of Patients With Pemphigus Vulgaris: A Pilot Study, Dermatologic Therapy (2020)
3. Pemphigus Disease and Area Index: Unmet Needs in the Real-World Management of Pemphigus, Oral Diseases (2023)
4. Efficacy and Safety of Biosimilar Rituximab in Patients With Pemphigus Vulgaris: A Prospective Observational Study, Journal of Dermatological Treatment (2021)
5. Iranian Guideline for Rituximab Therapy in Pemphigus Patients, Dermatologic Therapy (2019)
6. Burden of Pemphigus Vulgaris With a Particular Focus on Women: A Review, International Journal of Women's Dermatology (2022)
7. Retrospective Study of Gingival Involvement in Pemphigus: A Difficult to Treat Phenomenon, Dermatologic Therapy (2022)
8. Rituximab Monotherapy in Mild Pemphigus, Journal of Dermatological Treatment (2022)
Experts (# of related papers)
View all Related Experts
Maryam Daneshpajooh (32)
Hamid Reza Mahmoodi (26)
Other Related Docs
9. Applicability of Glucocorticoid Toxicity Index in Pemphigus: Comparison Between Two Groups of Rituximab-Treated and Rituximab-Naive Patients, Dermatologic Therapy (2022)
10. Covid-19: The Experience From Iran, Clinics in Dermatology (2021)
11. Factors Associated With the Healing Time of Pemphigus Vulgaris Oral Lesions: A Prospective Study, Oral Diseases (2023)
12. Short-Term Clinical and Serological Follow-Up With Conventional and Conformational Anti-Desmoglein Antibodies in Treatment-Naive and Previously Treated Patients With Pemphigus Vulgaris After Receiving Rituximab, International Journal of Women's Dermatology (2019)
13. Paradoxical Reaction to Rituximab in Patients With Pemphigus: A Report of 10 Cases, Immunopharmacology and Immunotoxicology (2020)
14. Assessing Quality of Life in Patients With Autoimmune Bullous Diseases Using the Persian Version of Treatment of Autoimmune Bullous Disease Quality of Life Questionnaire Finds Similar Effects in Women As Men, International Journal of Women's Dermatology (2022)
15. Evaluating the Risk-To-Benefit Ratio of Using Cotrimoxazole As a Pneumocystis Pneumonia Preventative Intervention Among Pemphigus Patients Treated With Rituximab: A Retrospective Study With 494 Patients, Dermatologic Therapy (2022)
16. Updated S2k Guidelines on the Management of Pemphigus Vulgaris and Foliaceus Initiated by the European Academy of Dermatology and Venereology (Eadv), Journal of the European Academy of Dermatology and Venereology (2020)
17. Current Status and Prospects for the Diagnosis of Pemphigus Vulgaris, Expert Review of Clinical Immunology (2021)
18. Pemphigus Patients With Initial Negative Levels of Anti-Desmoglein: A Subtype With Different Profile?, Dermatologic Therapy (2022)
19. Multiple Cycles of Rituximab Therapy for Pemphigus: A Group of Patients With Difficult- To-Treat Disease or a Consequence of Late Rituximab Initiation?, Dermatologic Therapy (2022)
20. Sixteen-Year History of Rituximab Therapy for 1085 Pemphigus Vulgaris Patients: A Systematic Review, International Immunopharmacology (2018)
21. Single-Nucleotide Polymorphisms Associated With Pemphigus Vulgaris: Potent Markers for Better Treatment and Personalized Medicine, International Journal of Immunogenetics (2020)
22. A Systematic Review on Efficacy, Safety, and Treatment-Durability of Low-Dose Rituximab for the Treatment of Pemphigus: Special Focus on Covid-19 Pandemic Concerns, Immunopharmacology and Immunotoxicology (2021)
23. Pregnancy Outcomes in Women With Pemphigus Exposed to Rituximab Before or During Pregnancy, International Journal of Women's Dermatology (2022)
24. Elevated Serum Level of B-Cell Activating Factor (Baff) After Rituximab Therapy in Pemphigus Vulgaris Patients Suggests a Possible Therapeutic Efficacy of B-Cell Depletion Therapies Combined With Anti-Baff Agents, International Journal of Dermatology (2023)
25. Investigating Expression Pattern of Eight Immune-Related Genes in Pemphigus Patients Compared With the Healthy Controls and After Rituximab Therapy: Potential Roles of Ctla4 and Fcgr3a Genes Expression in Outcomes of Rituximab Therapy, Dermatologic Therapy (2020)
26. What Is Novel in the Clinical Management of Pemphigus Vulgaris?, Expert Review of Clinical Pharmacology (2024)
27. Autoimmune Blistering Diseases Treated With Glucocorticoids: An International Study of Steroid-Induced Myopathy, Journal of the European Academy of Dermatology and Venereology (2025)
28. Frequency of Seropositivity Against Infectious Agents Amongst Pemphigus Vulgaris Patients: A Case-Control Study on Strongyloides Stercoralis, Helicobacter Pylori, Toxoplasma Gondii, Leishmania Major, and Epstein-Barr Virus, International Journal of Dermatology (2015)
29. Nanomedicine and Advanced Technologies for Burns: Preventing Infection and Facilitating Wound Healing, Advanced Drug Delivery Reviews (2018)
30. The Prevalence of S. Aureus Skin and Soft Tissue Infections in Patients With Pemphigus, Autoimmune Diseases (2016)
31. Comparing the Short-Term Therapeutic Effects and Safety Profiles of Rituximab Therapy in Pemphigus Vulgaris Patients Either Early Treated or Later Than Six Months, Journal of Dermatological Treatment (2019)
32. Desquamative Gingivitis in a Pemphigus Vulgaris Patient Resistant to Rituximab, Dermatologic Therapy (2020)
33. Adverse Outcome and Severity of Covid-19 in Patients With Autoimmune Bullous Diseases: A Historical Cohort Study, Dermatologic Therapy (2022)
34. Drug-Induced Pemphigus: A Systematic Review of 170 Patients, International Immunopharmacology (2021)
35. The Efficacy and Safety of Rituximab in Anca-Associated Vasculitis: A Systematic Review, Biology (2022)
36. Rituximab in Childhood and Juvenile Autoimmune Bullous Diseases As First-Line and Second-Line Treatment: A Case Series of 13 Patients, Journal of Dermatological Treatment (2020)